<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Giugliano, Robert</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence of Added Benefit with Edoxaban in Patients with Paroxysmal AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-22</style></pages><abstract><style  face="normal" font="default" size="100%">Among patients with atrial fibrillation (AF) treated with anticoagulants, differences in baseline characteristics only partially account for the differences in outcome by AF subtype. This article presents results of a secondary data analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48 trial [ENGAGE AF-TIMI 48; NCT00781391].</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>